Clinical Trial: Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis

Brief Summary:

Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it is currently heavily used in this population. In fact, per evidence of barcode scanning via Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for non Cystic fibrosis patients with an estimated yearly cost of $341,968.15.In vitro studies showed that the effect of Dnase was minimal on sputum viscosity when compared to Hypertonic saline . Furthermore recent studies on hypertonic saline in cystic fibrosis patients showed that it is an inexpensive and safe therapy when preceded by a bronchodilator in patients with cystic fibrosis.

We hereby propose a prospective randomized trial to compare the efficacy of hypertonic saline, DNase, vs. normal saline in the treatment of atelectasis in non cystic fibrosis, mechanically ventilated patient.

Detailed Summary:
Sponsor: University of Oklahoma

Current Primary Outcome: Chest x-ray atelectasis score [ Time Frame: 7 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome: PO2/FIO2, Mechanical ventilation days ICU days, [ Time Frame: 7 days ]

Original Secondary Outcome: Same as current

Information By: University of Oklahoma

Dates:
Date Received: April 30, 2008
Date Started: October 2006
Date Completion:
Last Updated: January 6, 2014
Last Verified: January 2014